MedTrace Logo

LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma

NCT03090659 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-06-12

No results posted yet for this study

Summary

This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of LCAR-B38M CAR-T cells in treating patients diagnosed with refractory/relapsed multiple myeloma (r/r MM).

Conditions

  • Refractory or Relapsed Multiple Myeloma

Interventions

BIOLOGICAL

LCAR-B38M CAR-T cell injection

Sponsors & Collaborators

  • Second Affiliated Hospital of Xi'an Jiaotong University

    collaborator OTHER

  • Ruijin Hospital

    collaborator OTHER

  • Jiangsu Provincial People's Hospital

    collaborator OTHER

  • Shanghai Changzheng Hospital

    collaborator OTHER

  • Nanjing Legend Biotech Co.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-02
Primary Completion
2023-12-31
Completion
2023-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03090659 on ClinicalTrials.gov